American Clinical Research Services Acquires Clinical Site Services and Patient Advertising Guru
American Clinical Research Services (“ACRS”) has announced the acquisition of Clinical Site Services (“CSSi”) and Patient Advertising Guru (“PAG”). The acquisition of the two previously merged companies demonstrates ACRS’s focus on inclusive patient centric solutions for clinical development. Both Chris Trizna (CSSi) and Evan Brett (PAG) remain as co-Presidents, joining the ACRS leadership team.
Clinical Site Services is a provider of customized, full-service site centric patient recruitment solutions. CSSi’s Local Enrollment Specialists are former study coordinators, located across the globe, that support sites to generate referrals from within the site, their community, advocacy groups, and local medical practitioners.
Patient Advertising Guru is a niche provider of advertising, providing creative development, media buying, and referral tracking services. PAG is also the creator of Research Study Rockstar, a social media resource for patient recruitment.
Both CCSi and PAG have experience servicing a range of therapeutic areas, including oncology, CNS, metabolic, and women’s health, across 50+ countries.
Reference
Latticework Capital Management’s American Clinical Research Services Acquires Clinical Site Services and Patient Advertising Guru. (2023, May 9). Business Wire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
